FDA Early Feasibility Studies (EFS): The Strategic Playbook for Novel Medical Devices

A comprehensive guide to the FDA Early Feasibility Studies (EFS) Program for medical devices. Dissects EFS IDE protocols, risk mitigation, and OHT routing.

For medical device innovators and startup founders, the journey from a bench prototype to clinical reality has historically been slow and capital-intensive. In the early 2000s, rigid regulatory requirements in the United States forced many sponsors to conduct their initial clinical evaluations overseas. This trend delayed U.S. patient access to cutting-edge therapies and limited early-stage clinical experience to international investigators.

To reverse this migration and encourage clinical research within the U.S., the FDA’s Center for Devices and Radiological Health (CDRH) introduced the Early Feasibility Studies (EFS) Program. Operating under the Investigational Device Exemption (IDE) regulations, the EFS framework allows sponsors to conduct early-stage, first-in-human clinical investigations of novel medical technologies under a highly flexible regulatory model.

This guide provides clinical affairs directors and regulatory strategists with a comprehensive playbook for navigating the FDA EFS pathway. It covers when to choose an EFS over a traditional feasibility study, the unique regulatory flexibilities of the EFS protocol, risk mitigation and subject enrollment design, the CDRH review structure, and the integration of pre-submission meetings.

Scenario Question: We are developing a highly novel, significant-risk implantable device with no prior clinical experience. When is an FDA Early Feasibility Study the right path under an IDE, how does it differ from a traditional clinical trial, and how do we engage the FDA EFS Program?

Direct Answer: An FDA Early Feasibility Study (EFS) is appropriate when a novel significant-risk device is in the early stages of development and nonclinical testing alone cannot resolve key clinical safety or performance questions. Unlike traditional feasibility or pivotal trials, an EFS requires a smaller subject cohort (typically 10 to 15 subjects) and allows a reduced nonclinical testing burden by postponing long-term durability testing. Built on the October 2013 FDA guidance (Docket FDA-2011-D-0787), EFS IDEs feature graduated enrollment schemes and structured change-control protocols that permit device design or procedural adjustments during the study without a new IDE supplement. Sponsors engage the EFS Program by routing a Pre-Submission (Q-Sub) proposal to one of the eight CDRH Office of Health Technology (OHT) review groups, establishing early alignment on benefit-risk profiles and nonclinical test requirements.

1. Understanding the Early Feasibility Study (EFS) Program

The FDA officially finalized the EFS Program with the publication of the guidance document, Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies, in October 2013 under Docket FDA-2011-D-0787. Celebrating its tenth anniversary in October 2023, the program has succeeded in reversing the overseas clinical migration, with CDRH data showing that the annual number of EFS IDE submissions and approvals more than doubled in the year after the guidance issued.

Key EFS Definitions

To understand the EFS pathway, sponsors must distinguish it from other clinical trial phases under the medical device clinical trials and IDE regulations:

Early Feasibility Study (EFS)

A limited clinical investigation of a device early in development, before the device design is finalized. It is designed to evaluate the device-to-tissue interface, assess initial clinical safety, and provide proof of principle. The sample size is small, typically enrolling 10 to 15 subjects (though occasionally up to 30), and is conducted under an approved IDE.

Traditional Feasibility Study

A clinical study designed to capture preliminary clinical safety and performance data on a near-final or finalized device design. It helps refine clinical protocols and endpoints before launching a large-scale registration study.

Pivotal Study

A large, statistically powered clinical trial designed to collect definitive evidence of safety and effectiveness for a finalized device design. It supports premarket approval (PMA), De Novo classification, or 510(k) clearance.

The Underlying Rationale

The core philosophy of the EFS Program is that clinical experience is often the only way to identify necessary engineering iterations for highly novel devices. In a traditional IDE pathway, the FDA requires complete, long-term nonclinical testing (e.g., millions of cycles of mechanical fatigue testing, long-term animal biocompatibility) before any human exposure is allowed.

For a novel technology, this creates a catch-22: a startup must spend millions of dollars on nonclinical validation of a design that they will likely need to change after the first five human procedures. The EFS Program solves this by permitting a reduced nonclinical testing burden. The FDA allows the sponsor to postpone some long-term nonclinical tests, provided the sponsor can justify safety through alternative risk-mitigation measures, clinical monitoring, and a robust benefit-risk analysis under ISO 14971.

2. Deciding When to Run an EFS: Strategic Decision Matrix

Choosing the EFS pathway is a major strategic decision. The program is open to devices destined for Premarket Approval (PMA), De Novo classification, Humanitarian Device Exemption (HDE), and select Premarket Notification (510k) pathways.

EFS Strategic Gating Questions

Clinical teams should evaluate the EFS pathway using four primary criteria:

1. Is the device design finalized?

If the device design is frozen and ready for production scale-up, an EFS is unnecessary. A traditional feasibility or pivotal study is more appropriate. If the clinical team expects that early human feedback will require adjustments to the implant dimensions, delivery catheter stiffness, or software control algorithms, the EFS is the ideal pathway because it allows in-study design modifications.

2. Can nonclinical testing resolve our safety questions?

For revolutionary technologies (such as novel transcatheter heart valves, brain-computer interfaces, or bioresorbable scaffolds), bench models and animal studies have major predictive limits. If the device-to-tissue interaction or the operator's learning curve cannot be modeled nonclinically, human clinical exposure under an EFS is the only path to gather meaningful safety data.

3. Are we prepared for intensive clinical monitoring and reporting?

An EFS requires a high level of sponsor oversight. The protocol will require frequent safety evaluations, independent data monitoring, and potentially more frequent Institutional Review Board (IRB) continuing reviews (e.g., semi-annually rather than annually) to protect the limited subject cohort.

4. Do we have the capital to iterate the design?

The main benefit of an EFS is the ability to modify the device during the study. However, manufacturing updated prototypes under current Good Manufacturing Practices (cGMP) and executing protocol amendments requires significant capital. Startups must ensure their funding runway can support these iterative cycles.

Table 1: EFS vs. Traditional Feasibility vs. Pivotal Studies

Parameter	Early Feasibility Study (EFS)	Traditional Feasibility	Pivotal Study
Primary Goal	Initial safety, proof of principle, design iteration	Preliminary safety & performance, protocol refinement	Definitive safety & effectiveness for registration
Device Design	Early prototype, not finalized	Near-final or finalized	Finalized and frozen
Subject Cohort	Small (typically 10–15; maximum 30)	Moderate (typically 20–50)	Large (often hundreds; statistically powered)
Nonclinical Burden	Reduced (postponed long-term testing)	Complete pre-clinical testing required	Complete pre-clinical testing required
Protocol Flexibility	High (in-study design/procedure changes allowed)	Moderate (requires formal IDE supplement)	Low (strict protocol compliance mandatory)
Regulatory Risk	High clinical uncertainty	Moderate clinical risk	Low clinical uncertainty

3. Risk Mitigation and Subject Enrollment Strategies

Because EFS sponsors are permitted to initiate human clinical work with less nonclinical data, the FDA requires enhanced clinical risk-mitigation measures. These safeguards are designed to protect the first human subjects while allowing the clinical team to gather actionable proof-of-principle data.

Graduated Enrollment Schemes

A standard EFS protocol does not allow the sponsor to enroll all 10 or 15 subjects simultaneously. Instead, the FDA requires a graduated enrollment scheme built on interim safety audits.

For example, a typical EFS enrollment progression is structured as follows:

Cohort A (Initial Safety): Enroll the first 3 subjects.
Safety Hold: Halt enrollment for a specified period (e.g., 30 days post-procedure) to evaluate the subjects for major adverse events.
Safety Audit: The Sponsor and the Clinical Data Monitoring Committee (DMC) review the clinical data and submit a report to the FDA.
Cohort B (Expanded Safety): Upon approval of the safety audit, enroll the next 5 subjects.
Final Cohort: Repeat the audit and enroll the remaining subjects up to the target sample size.

This graduated approach ensures that if a design flaw causes an adverse event, human exposure is limited to a very small cohort before the device is modified.

In-Study Design and Procedural Modifications

The most powerful regulatory feature of the EFS Program is the ability to make design or procedural changes during the study. In a traditional IDE, any change to the device design, manufacturing process, or clinical protocol requires the submission of a formal IDE Supplement, which triggers a mandatory 30-day FDA review period and halts clinical enrollment.

Under the EFS guidance, sponsors can include a structured change protocol in their original IDE application. This protocol defines the boundaries of changes the sponsor can make without submitting a new IDE supplement:

Design Changes: Sponsors can modify secondary device components (such as updating catheter handle materials or adjusting software parameters) and resume enrollment immediately, provided the change is validated through defined bench tests and reported to the FDA retrospectively in a 5-day notification or annual report.
Procedural Changes: If clinical experience shows that adjusting the implantation speed or modifying the post-operative anticoagulation protocol improves safety, the investigator can make these changes immediately, provided they are documented and reported.
Significant Changes: Major changes that alter the device’s core mechanism of action or significantly change the risk profile still require an IDE supplement, but the FDA committed to prioritizing EFS supplements to minimize clinical downtime.

Clinical Conduct Standards

To maintain data integrity and satisfy international regulators, EFS trials must comply with Good Clinical Practice (GCP) guidelines. Sponsors must conduct studies in alignment with the ISO 14155 clinical investigation of medical devices standard, ensuring that clinical data generated in the U.S. is acceptable for future CE marking submissions in Europe or PMDA submissions in Japan.

4. CDRH Office of Health Technology (OHT) Routing Table

The review of EFS IDE applications is managed by the Office of Health Technology (OHT) review groups within the FDA’s Office of Product Evaluation and Quality (OPEQ). The eight OHT offices are organized by clinical specialty, and each lists a dedicated EFS contact on the FDA EFS Program page. To streamline engagement, sponsors must identify the correct OHT for their device type before submitting a Pre-Submission:

Table 2: CDRH Office of Health Technology (OHT) EFS Routing

Office	Clinical Specialty	Representative Device Types
OHT 1	Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices	Intraocular lenses, ventilators, oxygen concentrators, sleep apnea devices, dental implants
OHT 2	Cardiovascular Devices	Pacemakers and ICDs, heart valves, coronary stents, ablation catheters, hemodynamic monitors
OHT 3	Gastrorenal, ObGyn, General Hospital, and Urology Devices	Hemodialysis machines, endoscopes, surgical mesh, IUDs, lithotripsy systems, urinary catheters
OHT 4	Surgical and Infection Control Devices	Surgical robots, wound-care systems, sterilizers, surgical drapes, personal protective equipment
OHT 5	Neurological and Physical Medicine Devices	Brain-computer interfaces, spinal cord stimulators, neurovascular devices, wheelchairs
OHT 6	Orthopedic Devices	Hip and knee implants, spinal fusion hardware, bone growth stimulators, fracture fixation plates
OHT 7	In Vitro Diagnostics	Molecular and immunoassay diagnostics, PCR test kits, point-of-care assays, IVD reagents
OHT 8	Radiological Health	CT scanners, MRI systems, X-ray and fluoroscopy, mammography, ultrasound, radiotherapy platforms

5. Pre-Submission Engagement and the EFS IDE Application

Filing an EFS IDE application without prior FDA engagement is a high-risk strategy that frequently leads to immediate application rejection or extensive requests for additional information. The FDA strongly encourages sponsors to utilize the Pre-Submission (Q-Sub) process to align on the clinical protocol and nonclinical testing requirements.

For a detailed review of Q-Sub timelines and documentation requirements, see our guide on FDA pre-submission and Q-submission strategies.

The EFS Pre-Submission Workflow

The pre-submission workflow for an EFS typically involves two sequential Q-Sub submissions:

SPONSOR WORKFLOW:
[Identify OHT Lead] ---> [Q-Sub 1: Nonclinical Test Plan] ---> [FDA Alignment Meeting]
                                                                        |
                                                                        v
[IDE Application Filed] <--- [Q-Sub 2: Draft Clinical Protocol] <--- [Define Risk-Mitigation]

Q-Sub 1: The Nonclinical Testing Plan

Sponsors present their proposed device design, clinical indication, and a detailed list of completed and planned bench, biocompatibility, and animal tests. Crucially, the sponsor highlights which traditional nonclinical tests they propose to postpone for the EFS, presenting a robust risk-mitigation rationale (such as intensive clinical monitoring or a restricted patient cohort). The FDA reviews this proposal and provides written feedback confirming whether the testing plan is sufficient to support human exposure.

Q-Sub 2: The Draft Clinical Protocol

Once the nonclinical plan is aligned, the sponsor submits a second Q-Sub containing the draft clinical protocol, the investigator training plan, the graduated enrollment scheme, the structured change protocol, and the draft informed consent document. This allows the sponsor to resolve clinical design concerns before the formal 30-day IDE clock starts.

Structure of the EFS IDE Application

The final EFS IDE application is compiled using the FDA eSTAR template or a traditional electronic format. The application must include:

Cover Letter: Explicitly stating that the application is a "Request for an Early Feasibility Study IDE."
Device Description: Detailed physical specifications, diagrams, and mechanism of action.
Nonclinical Data Summary: Bench test reports, biocompatibility reviews (ISO 10993), and acute animal study results.
Clinical Protocol: Including the graduated enrollment scheme and investigator qualifications.
Structured Change Protocol: Outlining the boundaries of permissible in-study modifications.
Investigator Brochure: A technical summary for clinical investigators.
Patient Informed Consent Document: Clearly disclosing the early-stage nature of the technology and the lack of guaranteed therapeutic benefit.

6. Operational Guidelines: ICF Design and MDIC EFS Site-Startup Tools

While clearing the FDA IDE gate is a regulatory milestone, executing an Early Feasibility Study requires overcoming major operational barriers. In particular, clinical trial site contracting, Institutional Review Board (IRB) reviews, and Informed Consent Form (ICF) design present unique challenges.

The Informed Consent Form (ICF) for an EFS is subject to strict FDA scrutiny. Because the device is in the early stages of development and has undergone a reduced nonclinical testing package, the risk profile is higher and less defined than in traditional trials.

According to FDA guidance, the ICF must:

Disclose the early-stage nature of the technology: State clearly that the device is a prototype under development and that long-term reliability and safety have not yet been fully validated on the bench.
Explain the potential for in-study modifications: Inform patients that minor changes may be made to the device design or the surgical procedure during the study based on safety data from previous subjects.
Manage therapeutic expectations: Explicitly state that the primary objective of the study is to evaluate safety and feasibility, and that the patient should not assume or expect direct therapeutic benefit from the procedure.
Highlight intensive follow-up: Detail the frequent clinical monitoring, imaging scans, and laboratory tests required, which may exceed standard-of-care follow-up.

MDIC EFS Site-Startup Tools

To resolve the operational bottlenecks that delay early-stage trials, the Medical Device Innovation Consortium (MDIC)—a public-private partnership of the FDA, industry, and clinical sites—has built a set of practical resources on top of its Blueprint for Early Feasibility Study Success. Two bottlenecks dominate: slow site contract negotiation and IRB review, which MDIC's own stakeholder surveys have consistently ranked among the top barriers to running EFS in the U.S.

A Standardized Master Clinical Trial Agreement (MCTA): MDIC publishes a master CTA template (developed with sponsors and major academic medical centers) that sites can adopt instead of negotiating bespoke contracts from scratch, shortening the legal review cycle that otherwise stalls study start-up.
Central IRB Use and the Clinical Site Alliance: The MDIC Blueprint recommends evaluating whether a central IRB is better suited to an EFS than each site's local IRB, and MDIC's Clinical Site Alliance unites experienced EFS sites to streamline study start-up and give U.S. patients earlier access to first-in-human devices.

The practical point for sponsors is that EFS timelines are governed as much by these operational mechanics — contracting, IRB review, and site readiness — as by the FDA IDE review itself, and MDIC's toolkits are designed to compress them.

7. Post-EFS Pathways: Transitioning to the Pivotal IDE

Completing the EFS is not the end of the clinical lifecycle. Once the last subject completes the follow-up window, the sponsor must aggregate the clinical safety data and formulate the transition plan. The outcomes of an EFS typically direct the sponsor down one of three pathways:

Pathway A: Design Iteration and EFS Extension

If the EFS reveals that the device requires significant modification (such as changing the implant geometry to prevent migration), the sponsor must freeze enrollment, implement the design change under their structured change protocol, and submit an IDE Supplement to resume enrollment. In some cases, the sponsor may request an extension of the EFS cohort size (e.g., adding another 10 subjects) to validate the modified design before moving forward.

Pathway B: Traditional Feasibility Study

If the device design is now frozen but the clinical team needs to gather more structured performance data to select endpoints for a registry or pivotal trial, they may transition to a traditional feasibility study. This study requires a new clinical protocol and complete nonclinical testing of the finalized design.

Pathway C: Direct-to-Pivotal Transition

If the EFS demonstrates exceptional safety and consistent proof of principle across the initial cohort, the sponsor can compile the EFS Clinical Study Report (CSR) and use it as the clinical justification to support a Pivotal Study IDE application. The EFS data helps justify the statistical power calculations, sample size, and primary safety/efficacy endpoints for the pivotal trial, accelerating the regulatory timeline to PMA or De Novo submission.

8. How EFS Connects to Breakthrough Device Designation

For companies developing highly innovative technologies, the EFS Program is frequently combined with the Breakthrough Devices Program. The Breakthrough Devices Program is designed to expedite the development, assessment, and review of medical devices that provide for more effective treatment of life-threatening or irreversibly debilitating conditions.

For a strategic breakdown of this program, see our guide on breakthrough device designation.

The Synergistic Pathway

Combining these two programs creates a powerful commercial and regulatory multiplier:

Early Access to FDA Leads: A device granted Breakthrough Designation receives prioritized interactive review. When applied to an EFS, this ensures that the sponsor has direct, rapid access to OHT review leads, accelerating the pre-submission and IDE clearance process.
Generating Early Clinical Evidence: One of the requirements for a PMA or De Novo submission under the Breakthrough pathway is the generation of robust clinical evidence. An EFS allows the sponsor to generate this initial clinical safety data in the U.S., which can then be used to design the subsequent pivotal trial.
Payer and CMS Alignment: The clinical evidence generated during an EFS and subsequent breakthrough trials serves as the foundation for future reimbursement negotiations. Payers look at EFS clinical safety and performance data to assess whether the technology qualifies for coverage under programs like Transitional Coverage for Emerging Technologies (TCET).

FAQ: FDA Early Feasibility Studies (EFS)

Can an EFS be done on a device with no prior clinical experience?

Yes. An EFS is explicitly designed for devices early in development, which frequently includes first-in-human studies with no prior clinical history. The program is also appropriate for devices that have been used previously outside the United States, devices used under Expanded Access, or marketed devices proposed for a new, significant-risk clinical indication.

How many subjects are typically enrolled in an EFS?

The subject cohort in an EFS is small, typically enrolling 10 to 15 subjects (often starting with a graduated cohort of 3 to 5 subjects). The FDA rarely approves an EFS exceeding 30 subjects, as larger cohorts are reserved for traditional feasibility or pivotal studies once the device design is finalized.

Is an EFS the same as a first-in-human study?

Not necessarily. While many EFS trials are first-in-human (FIH) studies, they are not synonymous. An FIH study is any clinical trial where a device is used in a human for the first time, regardless of the regulatory framework. An EFS is a specific, formal regulatory pathway defined by the FDA under the IDE regulations, featuring reduced nonclinical testing, structured change protocols, and graduated enrollment. An EFS can be conducted on a device that has already had limited human exposure outside the United States.

Sources

FDA EFS Program Page: U.S. Food and Drug Administration. Early Feasibility Studies (EFS) Program. Content current as of 05/05/2022. Available at: FDA EFS Program Page.
FDA EFS Guidance Document: U.S. Food and Drug Administration. Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies: Guidance for Industry and Food and Drug Administration Staff. Issued October 2013. Docket: FDA-2011-D-0787. Available at: FDA EFS Guidance Document.
MDIC EFS 10-Year Retrospective: Medical Device Innovation Consortium (MDIC). A Decade of Innovation in Medical Device Testing - EFS 10-year journey. October 2023. Available at: MDIC Celebrating EFS 10-Year Journey.
MDIC EFS Blueprint: Medical Device Innovation Consortium (MDIC). Blueprint for Early Feasibility Study Success. 2016. Available at: MDIC Blueprint for EFS Success.
Academic Article on Cures Act & EFS: Journal of American College of Cardiology (JACC): Cardiovascular Interventions. The 21st Century Cures Act and Early Feasibility Studies. Vol. 11, No. 23, 2018. Available at: ScienceDirect JACC Article.
IDE Regulations: Code of Federal Regulations. Title 21, Part 812 — Investigational Device Exemptions. Available at: eCFR Title 21 Part 812.
CDRH Office of Product Evaluation and Quality (OHT Structure): U.S. Food and Drug Administration. Office of Product Evaluation and Quality — lists OHT1 through OHT8 (Ophthalmic/Anesthesia/Respiratory/ENT/Dental, Cardiovascular, Gastrorenal/ObGyn/General Hospital/Urology, Surgical/Infection Control, Neurological/Physical Medicine, Orthopedic, In Vitro Diagnostics, Radiological Health). Available at: FDA OPEQ.
MDIC EFS Program Overview: Medical Device Innovation Consortium (MDIC). Early Feasibility Studies — Overview (EFS Blueprint, Master Clinical Trial Agreement template, Clinical Site Alliance, Accelerate EFS toolkit). Available at: MDIC Early Feasibility Studies.